#1 Clinical Trials Search in Europe

Bosentan

Bosentan, also known by its brand name Tracleer, is a medication that has been the subject of numerous clinical trials for its potential in treating various conditions, primarily pulmonary arterial hypertension (PAH). These trials have explored its efficacy, safety, and pharmacokinetics in different patient populations, including adults and children. The studies have also investigated its use in related conditions such as congenital heart defects and hypoxia-induced pulmonary hypertension.

Table of Contents

What is Bosentan?

Bosentan is a medication primarily used to treat various forms of pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. It is also known by its brand name Tracleer[1]. Bosentan belongs to a class of drugs called endothelin receptor antagonists, which work by blocking the action of a natural substance in the body that causes blood vessels to narrow[2].

How Does Bosentan Work?

Bosentan works by blocking the action of endothelin-1, a substance that causes blood vessels to constrict. By preventing this constriction, bosentan helps to lower the pressure in the pulmonary arteries, making it easier for the heart to pump blood through the lungs[3]. This mechanism of action is particularly beneficial for patients with pulmonary hypertension, as it can help improve their exercise capacity and overall quality of life.

Conditions Treated with Bosentan

Bosentan is primarily used to treat the following conditions:

  • Pulmonary Arterial Hypertension (PAH): This is the main condition for which bosentan is prescribed. It includes idiopathic PAH (with no known cause) and familial PAH (inherited form)[4].
  • PAH associated with congenital heart defects: Particularly in patients with Eisenmenger syndrome, a severe form of congenital heart disease[5].
  • PAH related to connective tissue diseases: Such as systemic sclerosis (scleroderma)[6].
  • Secondary pulmonary hypertension: This includes pulmonary hypertension due to severe mitral valve dysfunction or congestive heart failure[1].
  • Hypoxia-induced pulmonary hypertension: This can occur in conditions like high-altitude pulmonary edema[7].

Dosage and Administration

Bosentan is typically administered orally in tablet form. The dosage can vary depending on the patient’s age, weight, and specific condition:

  • Adults: The usual starting dose is 62.5 mg twice daily for 4 weeks, followed by an increase to the maintenance dose of 125 mg twice daily[2].
  • Children: A pediatric formulation is available as a 32 mg dispersible tablet. The dose is typically weight-based, starting at 2 mg/kg twice daily and potentially increasing to 4 mg/kg twice daily after 4 weeks[8].

It’s important to note that bosentan should be taken as prescribed by your doctor, and the dose should not be changed without medical supervision.

Effectiveness of Bosentan

Clinical trials have shown that bosentan can be effective in improving exercise capacity and symptoms in patients with PAH. Some key findings include:

  • Improved six-minute walk distance, a measure of exercise capacity[5].
  • Reduced Borg dyspnea index, indicating less breathlessness[5].
  • Improved WHO functional class, reflecting better overall functioning[5].
  • Potential benefits in reducing pulmonary artery pressure and improving right ventricular function[6].

Side Effects and Safety Considerations

While bosentan can be effective, it’s important to be aware of potential side effects and safety considerations:

  • Liver function abnormalities: Regular monitoring of liver enzymes is necessary[8].
  • Anemia: Decreases in hemoglobin levels may occur[8].
  • Fluid retention: This can manifest as edema or weight gain[2].
  • Headache and flushing: These are common side effects, especially when starting treatment[2].

It’s crucial to discuss any side effects with your healthcare provider and attend regular check-ups for monitoring.

Use in Special Populations

Bosentan has been studied in various patient groups:

  • Children: A pediatric formulation is available and has shown similar effectiveness and safety profile to adults[8].
  • Patients with congenital heart defects: Bosentan may be beneficial in patients with Eisenmenger syndrome or other complex congenital heart diseases[9].
  • Pregnancy: Bosentan is contraindicated during pregnancy due to potential risks to the fetus[2].

Ongoing Research and Future Prospects

Research on bosentan is ongoing, with studies exploring its potential benefits in various conditions:

  • Use in patients undergoing cardiac surgery to prevent right ventricular failure[10].
  • Potential effects on pulmonary artery remodeling in PAH[6].
  • Long-term safety and efficacy in pediatric patients[8].

These ongoing studies may provide further insights into the potential uses and benefits of bosentan in the future.

Aspect Details
Primary Conditions Studied Pulmonary Arterial Hypertension (PAH), Hypoxia-Induced Pulmonary Hypertension, Congenital Heart Defects
Patient Populations Adults and children with PAH, patients with Eisenmenger physiology, patients undergoing cardiac surgery
Dosage Forms Oral tablets, dispersible tablets for children
Common Dosing Regimens Adults: 62.5 mg twice daily, increased to 125 mg twice daily if tolerated Children: Weight-based dosing, typically 2 mg/kg twice or three times daily
Key Outcome Measures Exercise capacity (6-minute walk distance), WHO Functional Class changes, pulmonary artery pressure, right ventricular function, quality of life
Safety Monitoring Liver function tests, hemoglobin levels, growth parameters in children
Special Considerations Pediatric formulations developed, long-term safety and efficacy studies conducted

FAQ

  • What is Bosentan and how does it work? Bosentan is a dual endothelin receptor antagonist. It works by blocking the action of endothelin-1, a substance that causes blood vessels to narrow. By doing so, Bosentan helps to relax and widen blood vessels, particularly in the lungs, which can improve symptoms of pulmonary arterial hypertension.
  • What conditions is Bosentan being studied for in clinical trials? Bosentan is primarily being studied for pulmonary arterial hypertension (PAH). However, clinical trials have also explored its potential in treating hypoxia-induced pulmonary hypertension, congenital heart defects, and PAH related to Eisenmenger physiology.
  • Are there specific studies on Bosentan use in children? Yes, several clinical trials have focused on the use of Bosentan in children with PAH. These studies have investigated the pharmacokinetics, safety, and efficacy of pediatric formulations of Bosentan, as well as different dosing regimens for children.
  • What are some of the main outcomes measured in Bosentan clinical trials? Common outcomes measured in Bosentan trials include changes in exercise capacity (often measured by the 6-minute walk distance), changes in WHO functional class, pulmonary artery pressure, right ventricular function, and quality of life. Safety outcomes such as liver function and hemoglobin levels are also closely monitored.
  • How is Bosentan typically administered in these clinical trials? In most trials, Bosentan is administered orally, often starting with a lower dose (e.g., 62.5 mg twice daily) and then increasing to a higher maintenance dose (e.g., 125 mg twice daily) if well-tolerated. For children, weight-based dosing is used, and special pediatric formulations (such as dispersible tablets) have been developed.

Ongoing Clinical Trials on Bosentan

  • Study on Bosentan for Treating Coronary Artery Spasm in Patients with Ongoing Angina Symptoms

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

  • Study of bosentan, prednisone and prednisolone in patients with newly diagnosed or relapsing giant cell arteritis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Bosentan on Blood Pressure in Patients with Uncontrolled Hypertension

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Bosentan for Patients with Early Stage Non-Arteritic Anterior Ischemic Optic Neuropathy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Finland France Germany Hungary +7

Glossary

  • Pulmonary Arterial Hypertension (PAH): A condition characterized by high blood pressure in the arteries of the lungs, which can lead to shortness of breath, dizziness, and eventually heart failure.
  • Endothelin-1: A protein that causes blood vessels to narrow, particularly in the lungs. Bosentan works by blocking the action of this protein.
  • Bioequivalence: The property of two drug products having the same biological effect in the body. This is often studied when comparing different formulations of the same drug.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • WHO Functional Class: A system used to classify the severity of symptoms in patients with pulmonary hypertension, ranging from Class I (no limitation of physical activity) to Class IV (unable to carry out any physical activity without symptoms).
  • 6-minute Walk Distance: A test used to measure exercise capacity in patients with heart or lung disease, where the distance a patient can walk in 6 minutes is measured.
  • Eisenmenger Physiology: A condition where a heart defect causes blood to flow abnormally in the heart, leading to pulmonary hypertension.
  • Hypoxia: A condition where the body or a part of the body is deprived of adequate oxygen supply.
  • Congenital Heart Defect: A problem with the structure of the heart that is present at birth.
  • Borg Dyspnea Index: A scale used to measure perceived breathlessness, ranging from 0 (no breathlessness) to 10 (maximal breathlessness).

References

  1. https://clinicaltrials.gov/study/NCT01270750
  2. https://clinicaltrials.gov/study/NCT01352065
  3. https://clinicaltrials.gov/study/NCT04101370
  4. https://clinicaltrials.gov/study/NCT00319267
  5. https://clinicaltrials.gov/study/NCT00367770
  6. https://clinicaltrials.gov/study/NCT00595049
  7. https://clinicaltrials.gov/study/NCT00260819
  8. https://clinicaltrials.gov/study/NCT00319020
  9. https://clinicaltrials.gov/study/NCT01662037
  10. https://clinicaltrials.gov/study/NCT01184404